Suppr超能文献

圣乔治呼吸问卷在淋巴管肌瘤病中有纵向的结构有效性。

St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis.

机构信息

Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, Denver, CO.

Pediatrics Epidemiology Center, University of South Florida College of Medicine, Tampa, FL.

出版信息

Chest. 2013 Jun;143(6):1671-1678. doi: 10.1378/chest.12-0161.

Abstract

BACKGROUND

Lymphangioleiomyomatosis (LAM) is an uncommon, progressive, cystic lung disease that causes shortness of breath, hypoxemia, and impaired health-related quality of life (HRQL). Whether St. George's Respiratory Questionnaire (SGRQ), a respiratory-specific HRQL instrument, captures longitudinal changes in HRQL in patients with LAM is unknown.

METHODS

Using data from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus trial, we performed analyses to examine associations between SGRQ scores and values for four external measures (anchors). Anchors included (1) FEV₁, (2) diffusing capacity of the lung for carbon monoxide, (3) distance walked during the 6-min walk test, and (4) serum vascular endothelial growth factor-D.

RESULTS

SGRQ scores correlated with the majority of anchor values at baseline, 6 months, and 12 months. Results from longitudinal analyses demonstrated that SGRQ change scores tracked changes over time in values for each of the four anchors. At 12 months, subjects with the greatest improvement from baseline in FEV₁ experienced the greatest improvement in SGRQ scores (Symptoms domain, -13.4 ± 14.6 points; Activity domain, -6.46 ± 8.20 points; Impacts domain, -6.25 ± 12.8 points; SGRQ total, -7.53 ± 10.0 points). Plots of cumulative distribution functions further supported the longitudinal validity of the SGRQ in LAM.

CONCLUSIONS

In LAM, SGRQ scores are associated with variables used to assess LAM severity. The SGRQ is sensitive to change in LAM severity, particularly when change is defined by FEV₁, perhaps the most clinically relevant and prognostically important variable in LAM. The constellation of results here supports the validity of the SGRQ as capable of assessing longitudinal change in HRQL in LAM.

摘要

背景

淋巴管平滑肌瘤病(LAM)是一种罕见的进行性囊性肺疾病,可导致呼吸急促、低氧血症和健康相关生活质量(HRQL)受损。圣乔治呼吸问卷(SGRQ)是否能捕捉到 LAM 患者的 HRQL 纵向变化尚不清楚。

方法

使用多中心国际淋巴管平滑肌瘤病西罗莫司疗效和安全性试验的数据,我们进行了分析,以检查 SGRQ 评分与四个外部衡量标准(锚)之间的关联。锚包括(1)FEV₁、(2)一氧化碳弥散量、(3)6 分钟步行试验期间的步行距离和(4)血清血管内皮生长因子-D。

结果

SGRQ 评分与基线、6 个月和 12 个月时大多数锚值相关。纵向分析结果表明,SGRQ 变化评分与四个锚中每一个的随时间变化值相关。在 12 个月时,FEV₁从基线改善最大的患者,SGRQ 评分的改善最大(症状域,-13.4 ± 14.6 分;活动域,-6.46 ± 8.20 分;影响域,-6.25 ± 12.8 分;SGRQ 总分,-7.53 ± 10.0 分)。累积分布函数的图进一步支持了 SGRQ 在 LAM 中的纵向有效性。

结论

在 LAM 中,SGRQ 评分与用于评估 LAM 严重程度的变量相关。SGRQ 对 LAM 严重程度的变化敏感,特别是当变化由 FEV₁定义时,FEV₁可能是 LAM 中最具临床相关性和预后最重要的变量。这里的一系列结果支持了 SGRQ 作为评估 LAM 中 HRQL 纵向变化的有效性。

相似文献

引用本文的文献

7
Lymphangioleiomyomatosis: differential diagnosis and optimal management.淋巴管平滑肌瘤病:鉴别诊断与最佳治疗。
Ther Clin Risk Manag. 2014 Aug 21;10:691-700. doi: 10.2147/TCRM.S50784. eCollection 2014.

本文引用的文献

1
Efficacy and safety of sirolimus in lymphangioleiomyomatosis.西罗莫司治疗淋巴管平滑肌瘤病的疗效和安全性。
N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.
10
ATS statement: guidelines for the six-minute walk test.美国胸科学会声明:六分钟步行试验指南
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验